Clinical, subclinical characteristics of urinary tract infection and antibiotic susceptibility of the pathogenic bacteria in Hai Phong Medical University Hospital in 2023

  • Thành Tiến Đỗ
Keywords: Urinary tract infection (UTI), clinical, subclinical, bacteria, antibiotic susceptibility.

Abstract

Objectives: To describe clinical and subclinical characteristics of urinary tract infected patients in Hai Phong Medical University Hospital, to survey bacteria causing disease and their level of antibiotic susceptibility. Methods: a cross-sectional descriptive study was performed on 358 inpatients with a clinical diagnosis of urinary tract infection, assigned to a urine culture. Results: The disease was more common in women, accounting for 52.2%. The common age group was 60 years old and older (46.6%). Common clinical features were dysuria (89.1%), frequency (88.3%), cloudy urine (64.7%) and suprapubic pain (67.7%). The percentages of leukocytes > 10 G/L, NEU% > 70%, and CRP > 10 mg/dL in blood tests were 31.68%, 47.7% and 78.26%. A quick routine urine test revealed urinary red blood cell (+), urinary leukocyte (+), and urinary nitrite (+) in 85.31%, 68.53% and 13.29%. Common radiological findings were urolithiasis (35.2%), upper urinary tract dilation (30.26%), and bladder wall thickening (21.05%). The positive urine culture rate was 46.65%. There were 68.26%  gram-negative bacteria, with the most common being E. coli, and 32.74%  gram-positive bacteria, with the most common being Staphylococcus spp. 23.5%  E. coli strains produced ESBL, 8.9% Staphylococcus spp. resisted methicillin. E. coli was highly susceptible to Beta-lactam antibiotics combined with beta-lactamase inhibitors, Carbapeneme, Aminoglycoside, Colistin, Fosfomycin, and Nitrofurantoin; less susceptible to Quinolone, and Cephalosporin. Staphylococcus spp. were highly susceptible to Aminoglycoside, Cephalosporin, Nitrofurantoin, and Doxycycline; less susceptible to Quinolone; susceptibility to Vancomycin antibiotic was only 96.6%.

điểm /   đánh giá
Published
2025-01-08